Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer ; volume:28 ; number:9 ; day:22 ; month:6 ; year:2023 ; pages:1207-1217 ; date:9.2023
International journal of clinical oncology ; 28, Heft 9 (22.6.2023), 1207-1217, 9.2023
- Urheber
-
Nara, Katsuhiko
Taguchi, Ayumi
Yamamoto, Takehito
Hara, Konan
Tojima, Yuri
Honjoh, Harunori
Nishijima, Akira
Eguchi, Satoko
Miyamoto, Yuichiro
Sone, Kenbun
Mori, Mayuyo
Takada, Tappei
Osuga, Yutaka
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10147-023-02367-1
- URN
-
urn:nbn:de:101:1-2023110913143788646939
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nara, Katsuhiko
- Taguchi, Ayumi
- Yamamoto, Takehito
- Hara, Konan
- Tojima, Yuri
- Honjoh, Harunori
- Nishijima, Akira
- Eguchi, Satoko
- Miyamoto, Yuichiro
- Sone, Kenbun
- Mori, Mayuyo
- Takada, Tappei
- Osuga, Yutaka
- SpringerLink (Online service)
Ähnliche Objekte (12)
Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer
Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
High-expressed ACAT2 predicted the poor prognosis of platinum-resistant epithelial ovarian cancer
New Platinum(II) Complexes Affecting Different Biomolecular Targets in Resistant Ovarian Carcinoma Cells
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
Targeting SOD1 via RNAi with PEGylated graphene oxide nanoparticles in platinum-resistant ovarian cancer
Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer
Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer
Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
High-expressed ACAT2 predicted the poor prognosis of platinum-resistant epithelial ovarian cancer
New Platinum(II) Complexes Affecting Different Biomolecular Targets in Resistant Ovarian Carcinoma Cells
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
Targeting SOD1 via RNAi with PEGylated graphene oxide nanoparticles in platinum-resistant ovarian cancer
Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer
Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer
Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
High-expressed ACAT2 predicted the poor prognosis of platinum-resistant epithelial ovarian cancer
New Platinum(II) Complexes Affecting Different Biomolecular Targets in Resistant Ovarian Carcinoma Cells
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
Targeting SOD1 via RNAi with PEGylated graphene oxide nanoparticles in platinum-resistant ovarian cancer
Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer